Stojdl DF - Search Results

1

Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD. Pol JG, et al. Among authors: stojdl df. Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25. Mol Ther. 2014. PMID: 24322333 Free PMC article.

2

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Stojdl DF, et al. Nat Med. 2000 Jul;6(7):821-5. doi: 10.1038/77558. Nat Med. 2000. PMID: 10888934

3

The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC. Stojdl DF, et al. J Virol. 2000 Oct;74(20):9580-5. doi: 10.1128/jvi.74.20.9580-9585.2000. J Virol. 2000. PMID: 11000229 Free PMC article.

4

Oncolytic viruses: programmable tumour hunters.

Bell JC, Garson KA, Lichty BD, Stojdl DF. Bell JC, et al. Among authors: stojdl df. Curr Gene Ther. 2002 May;2(2):243-54. doi: 10.2174/1566523024605582. Curr Gene Ther. 2002. PMID: 12109220 Review.

5

Getting oncolytic virus therapies off the ground.

Bell JC, Lichty B, Stojdl D. Bell JC, et al. Cancer Cell. 2003 Jul;4(1):7-11. doi: 10.1016/s1535-6108(03)00170-3. Cancer Cell. 2003. PMID: 12892708 Free article.

6

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. Stojdl DF, et al. Cancer Cell. 2003 Oct;4(4):263-75. doi: 10.1016/s1535-6108(03)00241-1. Cancer Cell. 2003. PMID: 14585354 Free article.

7

Vesicular stomatitis virus: re-inventing the bullet.

Lichty BD, Power AT, Stojdl DF, Bell JC. Lichty BD, et al. Among authors: stojdl df. Trends Mol Med. 2004 May;10(5):210-6. doi: 10.1016/j.molmed.2004.03.003. Trends Mol Med. 2004. PMID: 15121047 Review.

8

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.

Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC. Lichty BD, et al. Among authors: stojdl df. Hum Gene Ther. 2004 Sep;15(9):821-31. doi: 10.1089/hum.2004.15.821. Hum Gene Ther. 2004. PMID: 15353037

9

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA. Lun X, et al. J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57. doi: 10.1093/jnci/djj413. J Natl Cancer Inst. 2006. PMID: 17077357

10

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC. Power AT, et al. Among authors: stojdl df. Mol Ther. 2007 Jan;15(1):123-30. doi: 10.1038/sj.mt.6300039. Mol Ther. 2007. PMID: 17164783 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page